316 related articles for article (PubMed ID: 16166768)
41. Thalidomide in multiple myeloma: past, present and future.
Harousseau JL
Future Oncol; 2006 Oct; 2(5):577-89. PubMed ID: 17026450
[TBL] [Abstract][Full Text] [Related]
42. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
43. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
44. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
45. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
46. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R
J Clin Oncol; 2003 Jan; 21(1):16-9. PubMed ID: 12506164
[TBL] [Abstract][Full Text] [Related]
47. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M
Eur J Haematol; 2005 Nov; 75(5):391-5. PubMed ID: 16191088
[TBL] [Abstract][Full Text] [Related]
48. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.
Zomas A; Anagnostopoulos N; Dimopoulos MA
Bone Marrow Transplant; 2000 Jun; 25(12):1319-20. PubMed ID: 10871741
[TBL] [Abstract][Full Text] [Related]
49. Future directions in multiple myeloma treatment.
Child JA; Russell N; Sonneveld P; Schey S
Acta Haematol; 2005; 114 Suppl 1():8-13. PubMed ID: 16166766
[TBL] [Abstract][Full Text] [Related]
50. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
51. Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Krejci M; Gregora E; Straub J; Minarik J; Scudla V; Adam Z; Krivanova A; Pour L; Zahradova L; Buchler T; Mayer J; Hajek R
Ann Hematol; 2011 Dec; 90(12):1441-7. PubMed ID: 21380511
[TBL] [Abstract][Full Text] [Related]
52. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
[TBL] [Abstract][Full Text] [Related]
53. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
Yakoub-Agha I; Attal M; Dumontet C; Delannoy V; Moreau P; Berthou C; Lamy T; Grosbois B; Dauriac C; Dorvaux V; Bay JO; Monconduit M; Harousseau JL; Duguet C; Duhamel A; Facon T
Hematol J; 2002; 3(4):185-92. PubMed ID: 12189564
[TBL] [Abstract][Full Text] [Related]
54. Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.
Hus M; Grzasko N; Szostek M; Pluta A; Helbig G; Woszczyk D; Adamczyk-Cioch M; Jawniak D; Legiec W; Morawska M; Kozinska J; Waciński P; Dmoszynska A
Ann Hematol; 2011 Oct; 90(10):1161-6. PubMed ID: 21698395
[TBL] [Abstract][Full Text] [Related]
55. Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N; Zabelina T; Klyuchnikov E; Kropff M; Pflüger KH; Burchert A; Stübig T; Wolschke C; Ayuk F; Hildebrandt Y; Bacher U; Badbaran A; Schilling G; Hansen T; Atanackovic D; Zander AR
Bone Marrow Transplant; 2013 Mar; 48(3):403-7. PubMed ID: 22863722
[TBL] [Abstract][Full Text] [Related]
56. Treatment of plasma cell dyscrasias with thalidomide and its derivatives.
Dimopoulos MA; Anagnostopoulos A; Weber D
J Clin Oncol; 2003 Dec; 21(23):4444-54. PubMed ID: 14645435
[TBL] [Abstract][Full Text] [Related]
57. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Mark TM; Coleman M; Niesvizky R
Leuk Res; 2014 May; 38(5):517-24. PubMed ID: 24690110
[TBL] [Abstract][Full Text] [Related]
58. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.
Dimopoulos MA; Anagnostopoulos A
Semin Hematol; 2003 Oct; 40(4 Suppl 4):8-16. PubMed ID: 15015891
[TBL] [Abstract][Full Text] [Related]
59. Trials investigate first-line thalidomide in multiple myeloma.
Owen OG
Lancet Oncol; 2005 Jan; 6(1):6. PubMed ID: 15672486
[No Abstract] [Full Text] [Related]
60. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
Kagoya Y; Nannya Y; Kurokawa M
Leuk Res; 2012 Aug; 36(8):1016-21. PubMed ID: 22579366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
